Pemeta Injection 500 mg/20 ml contains Pemetrexed, a potent antifolate chemotherapeutic agent used in the treatment of advanced cancers. It is primarily indicated for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma, offering targeted therapy against rapidly dividing tumor cells. Pemetrexed works by inhibiting key enzymes involved in folate metabolism, which are essential for DNA and RNA synthesis, thereby halting cancer cell growth and proliferation.

This high-dose injectable formulation is designed for intravenous administration in hospital or clinical settings under the supervision of trained oncology professionals. Pemeta Injection 500 mg/20 ml ensures accurate dosing for patients requiring larger treatment volumes or higher body surface area-based calculations.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Mechanism of Action

Pemetrexed inhibits multiple folate-dependent enzymes, including:

• Thymidylate synthase (TS) – essential for DNA synthesis

• Dihydrofolate reductase (DHFR) – maintains folate metabolism

• Glycinamide ribonucleotide formyltransferase (GARFT) – involved in purine synthesis

By targeting these enzymes, Pemetrexed disrupts nucleotide production, resulting in impaired DNA replication and RNA transcription. This selective mechanism affects rapidly dividing cancer cells more than normal cells, reducing tumor progression.

Indications

Pemeta Injection 500 mg/20 ml is indicated for:

• Non-small cell lung cancer (NSCLC): as monotherapy or in combination with cisplatin for advanced or metastatic disease

• Malignant pleural mesothelioma: in combination with cisplatin for patients not suitable for surgery

• Other solid tumors: under investigational protocols as determined by an oncologist

The therapy is tailored based on patient condition, cancer type, and prior treatment history.

Dosage and Administration

• Administered intravenously by a qualified healthcare professional

• Standard dosing is 500 mg/m² body surface area on day 1 of a 21-day cycle as a 10-minute IV infusion

• Pre-treatment with folic acid, vitamin B12, and corticosteroids is recommended to reduce toxicity

• Dose adjustments may be required for renal impairment or in the event of adverse effects

• Adequate hydration and monitoring of renal and hepatic function are essential during treatment

Benefits of Pemeta Injection

• Effective targeted therapy for advanced NSCLC and malignant pleural mesothelioma

• Inhibits tumor growth by blocking folate-dependent enzyme pathways

• Can be combined with platinum-based chemotherapy for enhanced efficacy

• Improves progression-free survival and quality of life in eligible patients

• Injectable form ensures precise dosing and rapid systemic delivery

Possible Side Effects

Common side effects include:

• Fatigue and weakness

• Nausea, vomiting, diarrhea

• Anemia, neutropenia, or thrombocytopenia

• Skin rash or pruritus

• Elevated liver enzymes

Serious but rare side effects may include:

• Severe myelosuppression

• Increased risk of infections

• Kidney toxicity

• Infusion-related reactions or allergic responses

Patients require regular monitoring of blood counts, liver and kidney function, and clinical assessments during therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Not recommended during pregnancy or breastfeeding

• Use with caution in patients with renal or hepatic impairment

• Ensure supplementation with folic acid and vitamin B12

• Monitor for drug interactions with other chemotherapeutic agents

• Administer only in settings equipped for emergency resuscitation

Storage

Store below 25°C in a dry place, protected from light. Do not freeze. Keep out of reach of children. Reconstituted solution should be used immediately according to clinical protocols.

Pemeta Injection 500 mg/20 ml offers advanced chemotherapy for high-dose requirements, providing targeted inhibition of tumor growth with improved clinical outcomes under professional supervision.